Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6921665

Title:Selective antibody targeting of undifferentiated stem cells
Inventors:McWhir, Jim; Midlothian, United Kingdom
Gold, Joseph D.; San Francisco, CA, USA
Schiff, J. Michael; Menlo Park, CA, USA
Summary:This invention describes novel polynucleotide-encoding glycosyltransferase enzymes, and a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The invention relates to cells containing an effector gene under the control of a transcriptional control element, such as the TERT promoter, which causes the gene to be expressed in relatively undifferentiated cells in the population. Further disclosed are means by which the expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences are provided which encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. Therapeutic applications are included, such as in tissue regeneration, drug screening, and in the treatment of conditions associated with hyperproliferation, such as cancers and other neoplasias.
Abstract:This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. The differentiated cell populations produced are suitable for use in tissue regeneration and non-therapeutic applications such as drug screening.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6921665
Application Number:US2001000995419
Date Filed:26/11/2001
Date Published:26/07/2005
Assignee:Roslin Institute (Edinburgh), Midlothian, United Kingdom Geron Corporation, Menlo Park, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021